Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmacology

Background:

• Bone scintigraphy is a widely used nuclear medicine imaging technique.
• It is highly effective for detecting metastatic bone disease in cancer patients.
• Technetium-99m (99mTc) labeled bis(di)phosphonates are the primary radiopharmaceuticals for diagnostic bone scans.

Purpose of the Study:

• To review bone physiology, radiopharmaceuticals, and uptake mechanisms in bone scintigraphy.
• To evaluate the efficacy of various bone-seeking radiopharmaceuticals for palliative treatment of bone metastases.
• To elucidate the radiobiological characteristics and clinical pain relief efficacy of radionuclides like 89Sr, 32P, 153Sm, 186Re, and 117Sn.

Main Methods:

• Review of bone scintigraphy principles, including bone physiology and radiopharmaceutical uptake.
• Analysis of diagnostic applications using 99mTc-labeled bis(di)phosphonates.
• Evaluation of therapeutic radionuclides (89Sr, 32P, 153Sm, 186Re, 117Sn) based on their radiobiological properties and clinical efficacy for pain management.

Main Results:

• Diagnostic bone scintigraphy effectively detects metastatic bone disease.
• Several radionuclides (89Sr, 32P, 153Sm, 186Re, 117Sn) are assessed for palliative treatment of bone metastases.
• Strontium-89 (89Sr) and Rhenium-186 (186Re) are identified as the preferred radionuclides for pain relief.

Conclusions:

• Strontium-89 (89Sr) and Rhenium-186 (186Re) are the radionuclides of choice for palliative bone metastasis treatment.
• Rhenium-186 (186Re) offers an advantage due to its imaging photons, enabling optimized dosimetry and application schemes.
• Bone scintigraphy remains a crucial diagnostic tool, while specific radiometals offer therapeutic benefits for bone metastases.